« Previous
Next »
Titles
- Biologic therapies for treatment of asthma associated with type 2 inflammation: effectiveness, value, and value-based price benchmarks : final evidence report1
- Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value1
- Dupilumab and crisaborole for atopic dermatitis: effectiveness and value : final evidence report and meeting summary1
- Emicizumab for hemophilia A with inhibitors: effectiveness and value : final evidence report1
- JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value : final evidence report1
- Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value : final report1
- Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value : final evidence report1